Prolongation of Pregnancy in Preeclampsia by Therapeutic Lipid Apheresis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2014-05-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Preeclampsia is a disease which occurs in about 6-8% of all pregnancies and is the main cause of maternal and fetal morbidity and mortality. The cause of preeclampsia is still not clear and the only therapy is preterm caesarean section. In severe preeclampsia an accumulation of triglyceride-rich lipoproteins occurs. Therefore, lipid apheresis is performed as lipid-removing therapy for treatment of preeclampsia in order to prolong pregnancy and provide the fetus more time for maturation. In this individual treatment patients with early preeclampsia (\<= 32 weeks of gestation) will be offered a H.E.L.P.-apheresis to postpone caesarean section and therefore prolong pregnancy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery

NCT01404910

Preeclampsia

COMPLETED NA

New Therapeutic Strategy Against Preeclampsia

NCT06464159

Preeclampsia

NOT_YET_RECRUITING

Prospective Study in Pregnant Women With Hypercoagulopathy

NCT00215969

Pre-Eclampsia Eclampsia

UNKNOWN

Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn

NCT01648855

Preterm Birth Intra-uterine Growth Restriction Maternal Preeclampsia +1 more

COMPLETED

Pre-Eclampsia Prediction By Doppler Screening Of Uterine Arteries And Angiogenic Factors In Second Trimester Of Pregnancy

NCT00725660

Pregnancy Pre Eclampsia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preeclampsia Dyslipidemia Proteinuria Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lipid apheresis

Lipid apheresis: lipid removing therapy,frequency and duration depending on the symptoms of mother and fetus.

Group Type EXPERIMENTAL

lipid apheresis

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lipid apheresis

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

H.E.L.P.-Apheresis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pregnant women
* early preeclampsia (\< 32 week of pregnancy)
* arterial hypertension during pregnancy
* proteinuria (=\> 1 + dipstick or 0\> 300 mg/24h)
* and/or intrauterine growth retardation (IUGR)
* informed consent